Expected budget savings on ustekinumab biosimilars in Europe

South Korea’s Samsung Bioepis presented data, including the budget impact analysis on ustekinumab biosimilars’ cost savings in Germany, the UK and Sweden at the 8th International Meeting on Intestinal Diseases in conjunction with the Annual Congress of the Korean Association for the Study of Intestinal Diseases (IMKASID 2025) held in Seoul, Korea.

Jeehoon Ghil, vice president and team leader of medical and lifecycle safety team at Samsung Bioepis, noted that the analyses “are pivotal for those considering biosimilars. Not only do they support the proven safety and efficacy of biosimilars but also highlight significant economic benefits for payers and patients,” and “we are committed to generating more relevant and meaningful data to continually build confidence in biosimilars and contribute to a sustainable healthcare ecosystem worldwide.”

The study, funded by Swiss generic and biosimilars drugmaker Sandoz (SIX: SDZ,) aimed to assess the cost-saving potential from the introduction of ustekinumab biosimilars from a payer perspective in Germany, the UK, and Sweden for adult patients currently treated with reference ustekinumab having Crohn’s disease (CD), psoriasis (PsO), and psoriatic arthritis (PsA).